MARIUSZ A. WASIK, MD, has been appointed Chair of the Department of Pathology at Fox Chase Cancer Center and Jeanes Hospital. He will also serve as Associate Director of the Cancer Center, a position he assumed on July 2, 2018.
As Chair of Pathology and a key member of Fox Chase’s leadership team, Dr. Wasik’s responsibilities will include playing a prominent role in supporting Temple University Health System’s cancer service line, faculty recruitment and retention, and strengthening the portfolio of molecular diagnostics and genomic testing within Fox Chase. He will also focus on developing a comprehensive genomic evaluation of patients’ cancers with an ultimate goal of identifying therapeutic targets.Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)
“Mariusz Wasik is an international leader in molecular hematopathology and translational research who will invigorate our Department of Pathology and enhance the Cancer Center’s diagnostic and clinical science portfolio,” said Richard I. Fisher, MD, President and Chief Executive Officer of Fox Chase Cancer Center.
Previous Roles and Research
DR. WASIK JOINS Fox Chase from the University of Pennsylvania, where he served in various positions in the Department of Pathology and Laboratory Medicine, including Director of Experimental Hematology, Director of the Hematopathology Fellowship Training Program, and Director of Hematopathology. Most recently, he was the principal investigator and scientific leader of the Translational Center of Excellence for Lymphoma at Abramson Cancer Center.
His research focuses primarily on aberrant cell signaling, the underlying genetic and epigenetic mechanisms in lymphomas, the development of new diagnostic and monitoring tools, and the identification of novel treatment approaches based on the unique biology of malignant cells.
A magna cum laude graduate of Wroclaw Medical University in his native Poland, Dr. Wasik completed a residency in anatomic pathology at the Mallory Institute of Pathology in Boston. In addition, he completed fellowships in basic immunology, tumor immunology, and hematopathology at Harvard Medical School/Boston University Medical Center, Harvard Medical School/Dana-Farber Cancer Institute, and Harvard Medical School/Beth Israel Hospital, respectively. ■